Rationale and design of a study to examine lower targets for low-density lipoprotein-cholesterol and blood pressure in coronary artery disease patients - The Japanese Coronary Artery Disease study II (JCADII)

Circulation Journal

Volumn 72, Issue 4, 2008, Pages 515-520

  Nagai, Ryozo ^a   Izumi, Tohru ^b   Kurabayashi, Masahiko ^c   Daida, Hiroyuki ^d   Tojo, Taiki ^b   Hasegawa, Akira ^c   Miyauchi, Katsumi ^d   Hayashi, Dobun ^a   Kohro, Takahide ^a   Okada, Yoshihiro ^a   Yamazaki, Tsutomu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aggressive therapy; Angiotensin receptor blockers; Coronary artery disease; PROBE study design; Statins

Indexed keywords

ATORVASTATIN; CANDESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; OPEN STUDY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RISK FACTOR; STENOSIS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHOLESTEROL, LDL; CLINICAL PROTOCOLS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 43549108535     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.515     Document Type: Article

References (35)

1. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 1986; 111: 383-390.
2. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 1998; 351: 1755-1762.
3. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290: 2805-2816.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
6. Pristipino C, Beltrame JF, Finocchiaro ML, Hattori R, Fujita M, Mongiardo R, et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation 2000; 101: 1102-1108.
7. Sekikawa A, Satoh T, Hayakawa T, Ueshima H, Kuller LH. Coronary heart disease mortality among men aged 35-44 years by prefecture in Japan in 1995-1999 compared with that among white men aged 35-44 by state in the United States in 1995-1998: Vital statistics data in recent birth cohort. Jpn Circ J 2001; 65: 887-892.
8. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty-five-year follow-up of the seven countries study. JAMA 1995; 274: 131-136.
9. Egusa G, Yamane K. Lifestyle, serum lipids and coronary artery disease: Comparison of Japan with the United States. J Atheroscler Thromb 2004; 11: 304-312.
10. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world: Seven Countries Study Research Group. N Engl J Med 2000; 342: 1-8.
11. Hayashi D, Yamazaki T. Design and rationale of the Japanese Coronary Artery Disease (JCAD) Study: A large-scale, multicentered prospective cohort study. Jpn Heart J 2004; 45: 895-911.
12. The Japanese Coronary Artery Disease (JCAD) Study Investigators. Current status of the background of patients with coronary artery disease in Japan: The Japanese Coronary Artery Disease Study (The JCAD Study). Circ J 2006; 70: 1256-1262.
13. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
14. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
15. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
16. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005; 294: 2437-2445.
17. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, et al. A reporting system on patients evaluated for coronary artery disease: Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51: 5-40.
18. Rakugi H, Ogihara T. Guidelines for treatment of hypertension: JSH2004. Nippon Ronen Igakkai Zasshi 2006; 43: 569-573 (in Japanese).
19. Teerakanchana T, Puavilai W, Suriyaprom K, Tungtrongchitr R. Comparative study of LDL-cholesterol levels in Thai patients by the direct method and using the Friedewald formula. Southeast Asian J Trop Med Public Health 2007; 38: 519-527.
20. Cordova CM, Schneider CR, Juttel ID, Cordova MM. Comparison of LDL-cholesterol direct measurement with the estimate using the Friedewald formula in a sample of 10,664 patients. Arc Bras Cardiol 2004; 83: 482-487; 476-481.
21. Sekikawa A, Ueshima H, Kadowaki T, El-Saed A, Okamura T, Takamiya T, et al. Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort. Am J Epidemiol 2007; 165: 617-624.
22. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366: 1279-1289.
23. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38: UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.
24. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
25. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
26. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: Secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1096-1100.
27. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
28. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1: 581-584.
29. Cruickshank J. The J-curve in hypertension. Curr Cardiol Rep 2003; 5: 441-452.
30. Hansson L. How far should blood pressure be lowered?: What is the role of the J-curve? Am J Hypertens 1990; 3: 726-729; Discussion 730-732.
31. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT): ALLHAT Collaborative Research Group. JAMA 2000; 283: 1967-1975.
32. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884-893.
33. Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: The Hisayama study. Arch Intern Med 2003; 163: 361-366.
34. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
35. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003; 41: 1341-1345.